Background: The growth rate of malignant facial skin tumors is one of the highest of all malignancies. The predominantly older patients mostly wish outpatient treatment. The aim of the study was to describe the strategy and results of outpatient tumor surgery. Based on two representative surveys, another objective was to establish whether it is useful to involve dentists in early cancer diagnosis.
Material And Methods: The retrospective case analysis comprised 77 patients (average age 67.8 years) in a private maxillofacial practice with a total of 100 malignant skin tumors. All patients were operated by the same surgeon. A frozen section analysis was carried out in 75 patients. Two surveys including 2500 participants each were conducted to determine the frequency of consultations with dermatologists for skin cancer checkup and the incidence of doctor-patient contacts among different specialists in the past 12 months.
Results: A total of 96% of the patients could be operated "in sano" in a one-stage procedure. Of these patients, 50% needed further intraoperative resections based on the frozen section analysis. Of the excisional defects, 71% could be closed by local flaps and 24% by skin grafting. Follow-up examinations after a mean of 34.6 months revealed one local recurrence. The surveys showed that only 17.4% of the interviewees contacted the general practitioner at least once every 2 years while 61.1% of those surveyed never had their skin examined. In the last 12 months, general practitioners were the most frequently consulted doctors (67.6% of the interviewees), followed by dentists in second place (44.1%). Other specialists were less frequently consulted.
Conclusions: One-stage outpatient treatment of malignant facial skin tumors in combination with frozen section analysis is a reliable and practicable method. After attending medical continuation courses, dentists should play a more active role in the prevention of skin cancer because of their frequent doctor-patient contacts.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s10006-001-0356-1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Actionable Gene Alterations Identified in Patients With Malignant Melanoma by Targeted Sequencing in Japan.
JCO Precis Oncol
January 2025
Department of Medical Oncology, Hokkaido University Hospital, Sapporo, Hokkaido, Japan.
Purpose: Precision medicine plays an important role in the treatment of patients with advanced melanoma. Despite its high incidence in White patients, advanced melanoma is rare in Asian countries, hampering prospective clinical trials targeting the Asian population. This retrospective study aimed to elucidate the real-world molecular diagnoses and outcomes of Japanese patients with melanoma using comprehensive genome profiling (CGP).
View Article and Find Full Text PDFDiagnostic Power of MicroRNAs in Melanoma: Integrating Machine Learning for Enhanced Accuracy and Pathway Analysis.
J Cell Mol Med
January 2025
Cancer Biology Research Center, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran.
This study identifies microRNAs (miRNAs) with significant discriminatory power in distinguishing melanoma from nevus, notably hsa-miR-26a and hsa-miR-211, which have exhibited diagnostic potential with accuracy of 81% and 78% respectively. To enhance diagnostic accuracy, we integrated miRNAs into various machine-learning (ML) models. Incorporating miRNAs with AUC scores above 0.
View Article and Find Full Text PDFShades of evidence: a review of skin color reporting in melanoma-related randomized controlled trials.
Arch Dermatol Res
January 2025
University of Mississippi Medical Center, Mississippi and JV "Sonny" Montgomery Veterans Hospital, Jackson, MS, USA.
Objectives: To examine the rate of skin color reporting in randomized controlled trials (RCTs) involving melanoma in the top ten highest dermatology journals by impact factor over the past four decades.
Methods: A systematic review of RCTs involving melanoma within the top ten dermatology journals, as determined by impact factor, was conducted from inception to July 10th, 2023. Studies were included if they reviewed the diagnosis and/or treatment of melanoma, were RCTs, directly involved patients and were written in English.
WT161, a selective HDAC6 inhibitor, decreases growth, enhances chemosensitivity, promotes apoptosis, and suppresses motility of melanoma cells.
Cancer Chemother Pharmacol
January 2025
Human Genetics Laboratory, Institute of Natural Sciences, Federal University of Alfenas (UNIFAL-MG), Alfenas, MG, 37130-001, Brazil.
Purpose: Histone deacetylase 6 (HDAC6) plays a critical role in tumorigenesis and tumor progression, contributing to proliferation, chemoresistance, and cell motility by regulating microtubule architecture. Despite its upregulation in melanoma tissues and cell lines, the specific biological roles of HDAC6 in melanoma are not well understood. This study aims to explore the functional effects and underlying mechanisms of WT161, a selective HDAC6 inhibitor, in melanoma cell lines.
View Article and Find Full Text PDFA Review of Current Treatment Options for Stage III and Stage IV Metastatic Melanoma.
S D Med
October 2024
Department of Internal Medicine, University of South Dakota Sanford School of Medicine, Sioux Falls, South Dakota.
The incidence of melanoma has increased for decades, and while surgical treatment of early stage disease is often curative, metastatic disease continues to have significant morbidity and mortality and carries a high associated health burden and economic cost. An expanding number of dermatologists are playing a key role in coordinating the care of patients with advanced melanoma, including in the setting of multidisciplinary melanoma clinics, many of which are anchored in dermatology departments. Advances in the understanding of the genetic and immunoregulatory aspects of melanoma development and progression have yielded a wave of novel therapeutics that has made significant impact on the approach to patients with metastatic disease.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!